Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Briacell Therapeutics Corp. (OTC: BCTXF).

Full DD Report for BCTXF

You must become a subscriber to view this report.


Recent News from (OTC: BCTXF)

Dr. William Williams, BriaCell's President & CEO, is Featured in an Exclusive New Audio Interview at SmallCapVoice.com
AUSTIN, Texas, Aug. 28, 2018 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President &...
Source: GlobeNewswire
Date: August, 28 2018 08:00
BriaCell Adds New Clinical Site To Phase IIa Study in Advanced Breast Cancer and Expands R&D Team
The addition of the Cancer Center of Kansas (CCK) as a new clinical trial site is expected to accelerate patient enrollment in both clinical trials. The hiring of Dr. Sunkari, an experienced Scientist, is intended to speed up the development of Bria-OTS™, BriaCell’s nov...
Source: GlobeNewswire
Date: August, 08 2018 06:30
BriaCell to Hold Conference Call on Key Clinical Findings; Activities
BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a Corporate ...
Source: GlobeNewswire
Date: June, 21 2018 10:09
BriaCell Therapeutics Corp. to Present at The MicroCap Conference on June 21st in Toronto at the Sheraton Centre Hotel
TORONTO, ON / ACCESSWIRE / June 13, 2018 / BriaCell Therapeutics Corp. ("BriaCell") (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will be presenting at this year's MicroCap Conference on June 21 st in Toro...
Source: ACCESSWIRE
Date: June, 13 2018 12:45
Dr. Williams, BriaCell Therapeutics Corp.'s President & CEO, Discusses Recent News and Progress in an Exclusive New Audio Interview with SmallCapVoice.com
AUSTIN, Texas, June 13, 2018 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT.V) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s...
Source: GlobeNewswire
Date: June, 13 2018 08:00
BriaCell Publishes Clinical Findings in 2018 American Society of Clinical Oncology (ASCO) Meeting
BERKELEY, Calif. and VANCOUVER, British Columbia, May 29, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it will publis...
Source: GlobeNewswire
Date: May, 29 2018 06:30
BriaCell's Lead Product Candidate's Novel Mechanism of Action Published in a Reputable Immunology Journal
BERKELEY, Calif. and VANCOUVER, British Columbia, May 21, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the publicat...
Source: GlobeNewswire
Date: May, 21 2018 06:30
BriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Sylve...
Source: GlobeNewswire
Date: April, 23 2018 06:30
BriaCell Provides Highlights of Scientific and Clinical Findings at AACR
BERKELEY, Calif. and VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it ha...
Source: GlobeNewswire
Date: April, 18 2018 09:30
Dr. Williams, BriaCell Therapeutics Corp.'s President & CEO, is Featured in an Exclusive New Audio Interview with SmallCapVoice.com
AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (TSXV:BCT.V) (OTC:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s P...
Source: GlobeNewswire
Date: April, 11 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-170.06480.0740.0740.064610,850
2018-12-140.06270.06270.06270.06273,000
2018-12-130.070.07250.07250.06853,285
2018-12-120.07060.0770.0770.070666,000
2018-12-110.0750.0760.0760.07514,000

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1785010,8507.8341Cover
2018-12-133,0003,28591.3242Short
2018-12-1114,00014,000100.0000Short
2018-12-1010,10010,100100.0000Short
2018-12-0623,00023,000100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BCTXF.


About Briacell Therapeutics Corp. (OTC: BCTXF)

Logo for Briacell Therapeutics Corp. (OTC: BCTXF)

BriaCell is an immuno oncology focused biotechnology company developing a targeted and safe approach to the management of cancer, including the first off the shelf personalized approach to immunotherapy. The company is currently conducting a Phase IIa clinical trial for its lead product candidate, Bria IMT, in patients with advanced breast cancer. This trial is listed in ClinicalTrials.gov as NCT . The trial is being conducted along with the co development of BriaDX, the Company s companion diagnostic test. Additionally, there is an FDA approved roll over combination study of Bria IMT with pembrolizumab Keytruda manufactured by Merck amp Co., Inc. or ipilimumab Yervoy manufactured by Bristol Myers Squibb Company for patients with advanced breast cancer previously treated with Bria IMT. The roll over trial is listed in ClinicalTrials.gov as NCT . Additionally, BriaCell is developing Bria OTS, the first off the shelf personalized treatment for advanced stage Breast Cancer. Finally, BriaCell s small molecule program consists of novel, selective protein kinase C delta PKCo inhibitors. PKCo inhibitors have shown activity in a number of pre clinical models of RAS genes transformed cancers including breast, pancreatic, non small cell lung cancer, melanoma and neuroendocrine tumors such as carcinoid tumors . This technology also has applications for treating patients with fibrotic diseases

 

 

 

Current Management

  • William V. Williams, MD / CEO
  • Gadi Levin / CFO
    • Mr. Gadi Levin, age , Chief Financial Officer. Mr. Levin has over years of experience working with public US, Canadian and multijurisdictional public companies. Mr. Levin currently serves as Chief Financial Officer of Briacell Therapeutics Corp OTCQB: BCTXF, TSXV: BRIA.V and Adira Energy Limited OTCMKTS:ADENF, TSX.V: ADL.V . Previously, Mr. Levin served as Chief Financial Officer of DarioHeath Corp NASDAQ: DRIO , a mHealth company operating in the field diabetes management. Mr. Levin also served as the Vice President of Finance and Chief Financial Officer for two Israeli investment firms specializing in private equity, hedge funds and real estate. Mr. Levin began his CPA career at the accounting firm, Arthur Andersen, where he worked for nine years, specializing in U.S. listed companies involved in IPO s working with US GAAP and IFRS. Mr. Levin has a Bachelor of Commerce degree in Accounting and Information Systems from the University of the Cape Town, South Africa, and a post graduate diploma in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa and has an MBA from Bar Ilan University in Israel.
  • Farrah Dean / VP, Corp. Dev.
  • Dr. Saeid Babaei / Chairman
  • William V. Williams, MD /
  • Martin Schmieg /
  • Rahoul Sharan /
  • Dr. Charles Wiseman /

Current Share Structure

  • Market Cap: $9,586,500 - 03/16/2018
  • Issue and Outstanding: 91,300,000 - 12/27/2016
  • Float: 72,270,000 - 12/27/2016

 


Recent Filings from (OTC: BCTXF)

Interim Financial Report - Condensed Interim Consolidated Financial Statements For the Three Months Ended October 31, 2017
Filing Type: Interim Financial Report - Condensed Interim Consolidated Financial Statements For the Three Months Filing Source: OTC Markets
Filing Date: January, 02 2018
Interim Financial Report - 52-109FV2 - Certification of interim filings - CFO (E)
Filing Type: Interim Financial Report - 52-109FV2 - Certification of interim filings - CFO (E)Filing Source: OTC Markets
Filing Date: January, 02 2018
Interim Financial Report - 52-109FV2 - Certification of interim filings - CEO (E)
Filing Type: Interim Financial Report - 52-109FV2 - Certification of interim filings - CEO (E)Filing Source: OTC Markets
Filing Date: January, 02 2018
Supplemental Information - 52-109FV1 - Certification of annual filings - CEO (E)
Filing Type: Supplemental Information - 52-109FV1 - Certification of annual filings - CEO (E)Filing Source: OTC Markets
Filing Date: November, 24 2017
Supplemental Information - Form 52-109FV1, Certification of Annual Filings (CFO)
Filing Type: Supplemental Information - Form 52-109FV1, Certification of Annual Filings (CFO)Filing Source: OTC Markets
Filing Date: November, 24 2017
Management Discussion and Analysis - Managements Discussion and Analysis For The Year Ended July 31, 2017
Filing Type: Management Discussion and Analysis - Managements Discussion and Analysis For The Year Ended July 31,Filing Source: OTC Markets
Filing Date: November, 24 2017
Annual Report - Consolidated Financial Statements For the Years Ended July 31, 2017 and 2016
Filing Type: Annual Report - Consolidated Financial Statements For the Years Ended July 31, 2017 and 2016Filing Source: OTC Markets
Filing Date: November, 24 2017

 

 


Daily Technical Chart for (OTC: BCTXF)

Daily Technical Chart for (OTC: BCTXF)


Stay tuned for daily updates and more on (OTC: BCTXF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BCTXF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BCTXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BCTXF and does not buy, sell, or trade any shares of BCTXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/